- Home
- COKE vs BBIO Comparison
COKE vs BBIO Comparison
Compare COKE & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COKE
- BBIO
- Stock Information
- Founded
- COKE 1902
- BBIO 2015
- Country
- COKE United States
- BBIO United States
- Employees
- COKE N/A
- BBIO N/A
- Industry
- COKE Beverages (Production/Distribution)
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- COKE Consumer Staples
- BBIO Health Care
- Exchange
- COKE Nasdaq
- BBIO Nasdaq
- Market Cap
- COKE 10.0B
- BBIO 10.4B
- IPO Year
- COKE N/A
- BBIO 2019
- Fundamental
- Price
- COKE $132.49
- BBIO $63.37
- Analyst Decision
- COKE
- BBIO Strong Buy
- Analyst Count
- COKE 0
- BBIO 17
- Target Price
- COKE N/A
- BBIO $72.35
- AVG Volume (30 Days)
- COKE 491.2K
- BBIO 2.6M
- Earning Date
- COKE 10-29-2025
- BBIO 10-29-2025
- Dividend Yield
- COKE 0.75%
- BBIO N/A
- EPS Growth
- COKE 22.14
- BBIO N/A
- EPS
- COKE 7.03
- BBIO N/A
- Revenue
- COKE $7,070,308,000.00
- BBIO $353,780,000.00
- Revenue This Year
- COKE N/A
- BBIO $115.12
- Revenue Next Year
- COKE N/A
- BBIO $65.29
- P/E Ratio
- COKE $18.85
- BBIO N/A
- Revenue Growth
- COKE 4.22
- BBIO 62.46
- 52 Week Low
- COKE $105.21
- BBIO $21.72
- 52 Week High
- COKE $146.09
- BBIO $69.48
- Technical
- Relative Strength Index (RSI)
- COKE 66.60
- BBIO 66.45
- Support Level
- COKE $126.75
- BBIO $52.75
- Resistance Level
- COKE $129.49
- BBIO $69.48
- Average True Range (ATR)
- COKE 3.03
- BBIO 2.78
- MACD
- COKE 0.09
- BBIO 0.97
- Stochastic Oscillator
- COKE 58.59
- BBIO 63.48
About COKE Coca-Cola Consolidated Inc.
Coca-Cola Consolidated Inc distributes, markets and manufactures nonalcoholic beverages. It offer a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages and the Company's principal sparkling beverage is Coca Cola. Still beverages include energy products and noncarbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices and sports drinks. The Company has three operating segments: Nonalcoholic Beverages, All Other and Eliminations. key revenue is generated from Nonalcoholic Beverages.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.